首页 > 文献资料
-
阿司匹林在动脉粥样硬化性心血管疾病中的临床应用:中国专家共识(2016)
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and has the lagest disease burden in China.Aspirin is the most promising agent for the prevention of ASCVD in such a large population for its easy availability and relative effectiveness,although its use in primary prevention is still a subject of debate.The joint task force has reviewed the current evidence of aspirin use in healthy population and in patients with stable coronary artery disease,acute coronary syndrome,transient ischemic attack,stroke and peripheral artery disease.The consensus statement provides a practical algorithm for identifying those at a high 10-year ASCVD risk,with more than or equal to 10％,who may benefit from aspirin use.Recommendations for aspirin use in primary and secondary prevention of ASCVD in Chinese,as well as its safety and "resistance" issues,are also stated.
-
阿司匹林在动脉粥样硬化性心血管疾病中的临床应用：中国专家共识（2016）
一、前言
动脉粥样硬化血栓形成（ atherothrombosis ）是影响心、脑血管和外周动脉的全身系统性病理生理过程，可导致冠状动脉疾病［稳定性冠状动脉疾病（ SCAD ）、非ST段抬高型急性冠状动脉综合征（ NSTE-ACS）和急性ST段抬高型心肌梗死（STEMI）］、缺血性脑血管病、短暂性脑缺血发作（TIA）及外周动脉疾病（PAD）等［1］。为规范阿司匹林在动脉粥样硬化性心血管疾病（atherosclerotic cardiovascular disease ，ASCVD）中的应用并提高我国广大临床医师对于阿司匹林的认识，中华医学会老年医学分会牵头组织心脏病学、内分泌学、神经病学、血液病学、消化病学与肾脏病学相关专家，在“阿司匹林在动脉粥样硬化性心血管疾病中的临床应用：中国专家共识（2005）”［2］的基础上，回顾近10年的循证医学证据，参考国内［3-23］以及欧美发达国家相关指南／共识和建议［24-46］，结合中国国情和临床现状，充分讨论并更新形成本共识。
